Ladenburg analyst Michael Higgins lowered the firm’s price target on Marinus Pharmaceuticals to $13 from $15 and keeps a Buy rating on the shares post the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNS:
